Condition: Breast Cancer · Metastatic Breast Cancer · Advanced Breast Cancer · Sponsor: Reshma L. Mahtani, D.O.
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.
This description comes directly from the study's public registry record.
Reshma L Mahtani, D.O. · (786) 596-2000 · rmahtani@baptisthealth.net
Krystal Fernandez · (786) 596-2000 · krystal.fernandez@baptisthealth.net
Always discuss trial participation with your own doctor first.
| UCLA Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Not Yet Recruiting |
| Miami Cancer Institute at Baptist Health, Inc. | Miami, Florida, United States | Recruiting |
| Winship Cancer Institute at Emory University | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06263543